MetLife (NYSE:MET – Get Free Report) is expected to be announcing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of $2.77 per share and revenue of $19.86 billion for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 9:00 AM ET.
MetLife (NYSE:MET – Get Free Report) last announced its earnings results on Wednesday, August 5th. The financial services provider reported $2.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.13. The firm had revenue of $13.52 billion for the quarter, compared to analyst estimates of $19.67 billion. MetLife had a net margin of 4.57% and a return on equity of 23.39%. MetLife’s revenue was up 10.5% compared to the same quarter last year. During the same quarter last year, the business earned $2.02 earnings per share. On average, analysts expect MetLife to post $9.94 EPS for the current fiscal year and $10.72 EPS for the next fiscal year.
MetLife Stock Up 0.9%
MET stock opened at $100.92 on Tuesday. The stock has a market capitalization of $64.94 billion, a P/E ratio of 19.33, a PEG ratio of 0.94 and a beta of 0.78. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.20 and a current ratio of 0.20. MetLife has a one year low of $67.33 and a one year high of $103.65. The company has a 50 day moving average price of $97.82 and a two-hundred day moving average price of $85.80.
MetLife announced that its board has initiated a stock repurchase program on Wednesday, August 5th that allows the company to buy back $3 billion in outstanding shares. This buyback authorization allows the financial services provider to purchase up to 4.8% of its shares through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.
MetLife Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 3rd will be paid a dividend of $0.5925 per share. This represents a $2.37 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Tuesday, November 3rd. MetLife’s dividend payout ratio is currently 45.40%.
Analyst Ratings Changes
A number of equities research analysts have recently commented on MET shares. Weiss Ratings reaffirmed a “buy (b)” rating on shares of MetLife in a research report on Friday, September 11th. JPMorgan Chase & Co. upped their target price on MetLife from $108.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday, October 15th. Atlantic Securities set a $103.00 target price on MetLife in a research report on Wednesday, July 15th. Keefe, Bruyette & Woods raised their price target on MetLife from $105.00 to $108.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 11th. Finally, Barclays lifted their price target on MetLife from $97.00 to $111.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Thirteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $105.44.
Check Out Our Latest Analysis on MetLife
MetLife Company Profile
MetLife, Inc (NYSE: MET) is a global financial services company that provides insurance, retirement, and employee benefits solutions to individuals, employers, and institutions. Its offerings include life insurance, dental and vision coverage, accident and disability insurance, annuities, retirement savings products, and related financial services.
Through its institutional and workplace businesses, MetLife helps employers provide benefits and retirement programs to their employees. The company also serves individual customers with protection and income products.
Featured Stories
- Five stocks we like better than MetLife
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AIāThese 5 Stocks Are Getting Paid
Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.
